Comprehensive mutagenesis identifies the peptide repertoire of a p53 T-cell receptor mimic antibody that displays no toxicity in mice transgenic for human HLA-A*0201
Fig 2
Transcript expression of genes encoding T1-116C cross-reactive peptides in cancer cell lines and in normal human tissues.
Quantitative real time PCR (qPCR) analysis of transcript expression for (A) SHANK1, (B) UBR3 and (C) BSN in cancer cell lines (left) and in normal human tissues (right). For the qPCR analysis of transcript expression in cancer cell lines, transcript expression was determined using a Taqman probe that corresponds to the cross-reactive peptides. Expression was normalized to TBP, 18S RNA and HPRT1 and expressed relative to expression in control cancer cell lines (MDA-MB-453 for UBR3 and BSN, or ACH-N for SHANK1). The coding exon for the cross-reactive peptides is exon 5 (Ex5) for BSN, Ex22 for SHANK1 and UBR3. For the cancer cell lines, combined data from three replicate experiments is presented, whereas for the normal human tissues the MTCTM Panels are composed of samples from at least five different tissues and the results of one representative experiment are presented. For the normal human tissues, Clontech’s Human MTCTM Panel I and II were used to analyse transcript expression using a Taqman probe corresponding to the exon encoding the cross-reactive peptide. Expression was normalized to GAPDH and B2M and expressed relative to a control cancer cell line (MDA-MB-453 for UBR3 and BSN, or ACH-N for SHANK1).